In contrast, older WT mice showed a significant decrease in the amount of growth relative to young mice (1.37- vs 1.83-fold), while older KO mice had a growth response that was similar to the young mice (1.74- vs. 1.90-fold).
As can be seen in Fig. 3A, pig insulin blood levels were markedly enhanced in Factor VIII KO SCID mice compared to Factor VIII positive SCID mice, reflecting a growth advantage in the Factor VIII KO recipients.
We also assessed if the tumors implanted in syngeneic mice had a growth advantage over tumors implanted in nude mice.
Since body weight is a simple measure of the overall drug effect on the mouse phenotype, we measured body weight at different times during the trial and found that arginine butyrate had no significant effect on body weight, with arginine butyrate-treated mice showing a growth pattern indistinguishable from that of saline-treated mice.
As a result, paternal Igf2 mRNA levels are reduced, and the mice display a growth restriction phenotype.
We implanted in total more than 30 patient breast tumor tissue samples in mice, with a growth take rate of approximately 28% (Table 2).
We examined tumour incidence in transgenic mice expressing a growth hormone (GH) antagonist and in non-transgenic littermates following exposure to dimethylbenz[ a]anthracene (DMBA), a well characterized murine mammary gland carcinogen.
A similar mechanism may exist in vivo since we find that serum from athymic mice contains a growth inhibitory activity towards MCF-7 cells and the inhibitory effect can be abolished by oestradiol.
Kunugita et al (2001) examined the effect of radiotherapy after HBO in SCCVII tumours (radiobiological hypoxic fraction: approximately 10%) subcutaneously transplanted into C3H/He mice using a growth delay assay.
This activity of CD95 as a survival factor seems to be mostly relevant to cancer cells, as none of the normal tissues during embryonic development in either CD95 or CD95L knockout mice showed a growth defect or signs of cell death.
